Clusterin Antikörper (AA 331-449)
Kurzübersicht für Clusterin Antikörper (AA 331-449) (ABIN685342)
Target
Alle Clusterin (CLU) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 331-449
-
Kreuzreaktivität
- Human, Maus, Ratte
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human Apolipoprotein J
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
WB 1:300-5000
ELISA 1:500-1000
FCM 1:20-100
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
-
Haltbarkeit
- 12 months
-
-
-
A systems level analysis of epileptogenesis-associated proteome alterations." in: Neurobiology of disease, Vol. 105, pp. 164-178, (2017) (PubMed).
: "Time-dependent decrease of clusterin as a potential cerebrospinal fluid biomarker for drug-resistant epilepsy." in: Journal of molecular neuroscience : MN, Vol. 54, Issue 1, pp. 1-9, (2014) (PubMed).
: "
-
A systems level analysis of epileptogenesis-associated proteome alterations." in: Neurobiology of disease, Vol. 105, pp. 164-178, (2017) (PubMed).
-
- Clusterin (CLU)
-
Andere Bezeichnung
- Apolipoprotein J
-
Hintergrund
-
Synonyms: CLI, AAG4, APOJ, CLU1, CLU2, KUB1, SGP2, APO-J, SGP-2, SP-4, TRPM2, TRPM-2, NA1/NA2, Clusterin, Aging-associated gene 4 protein, Apolipoprotein J, Complement cytolysis inhibitor, Complement-associated protein SP-4,4, Ku7-binding protein 1, Testosterone-repressed prostate message 2, CLU
Background: Isoform 1 functions as extracellular chaperone that prevents aggregation of nonnative proteins. Prevents stress-induced aggregation of blood plasma proteins. Inhibits formation of amyloid fibrils by APP, APOC2, B2M, CALCA, CSN3, SNCA and aggregation-prone LYZ variants (in vitro). Does not require ATP. Maintains partially unfolded proteins in a state appropriate for subsequent refolding by other chaperones, such as HSPA8/HSC7. Does not refold proteins by itself. Binding to cell surface receptors triggers internalization of the chaperone-client complex and subsequent lysosomal or proteasomal degradation. Secreted isoform 1 protects cells against apoptosis and against cytolysis by complement. Intracellular isoforms interact with ubiquitin and SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complexes and promote the ubiquitination and subsequent proteasomal degradation of target proteins. Promotes proteasomal degradation of COMMD1 and IKBKB. Modulates NF-kappa-B transcriptional activity. Nuclear isoforms promote apoptosis. Mitochondrial isoforms suppress BAX-dependent release of cytochrome c into the cytoplasm and inhibit apoptosis. Plays a role in the regulation of cell proliferation.
-
Gen-ID
- 1191
-
UniProt
- P10909
-
Pathways
- Apoptose, Negative Regulation of intrinsic apoptotic Signaling
Target
-